Published: May 1, 2020

Introduction {#sec1}
============

It is believed that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously termed nCoV-2019) was introduced into the human population from a poorly characterized animal reservoir in late 2019 ([@bib4], [@bib34], [@bib43], [@bib44]). The epicenter of the subsequent SARS-CoV-2 spread was Wuhan, Hubei province, China, with more than 65,000 cases occurring in this area ([@bib36]). However, infections have now been detected in more than 110 countries and massive outbreaks are currently ongoing in the United States, Italy, and Spain ([@bib36], [@bib35]). Understanding which features of SARS-CoV-2 are essential for infection of human cells should provide insights into viral transmissibility and pathogenesis and might reveal targets for intervention.

The spike protein of coronaviruses is incorporated into the viral envelope and facilitates viral entry into target cells. For this, the surface unit S1 binds to a cellular receptor while the transmembrane unit S2 facilitates fusion of the viral membrane with a cellular membrane ([@bib8], [@bib11], [@bib23]). Membrane fusion depends on S protein cleavage by host cell proteases at the S1/S2 and the S2′ site ([Figure 1](#fig1){ref-type="fig"} A), which results in S protein activation ([@bib8], [@bib11], [@bib23]). Cleavage of the S protein can occur in the constitutive secretory pathway of infected cells or during viral entry into target cells and is essential for viral infectivity. Therefore, the responsible enzymes constitute potential targets for antiviral intervention.Figure 1The Multibasic Motif at the S1/S2 Cleavage Site of SARS-2-S Is Unique among Related Group 2b Betacoronaviruses(A) Schematic illustration of a coronavirus spike glycoprotein in which functional domains and cleavage sites are highlighted (RBD, receptor-binding domain; RBM, receptor-binding motif; TD, transmembrane domain).(B) Protein models for SARS-S and SARS-2-S based on the PDB: 5X5B structure ([@bib39]) as a template. Colored in red are the S1/S2 and S2′ cleavage sites. Further, the S1 subunit (blue), including the RBD (purple), and the S2 subunit (gray) are depicted.(C and D) Amino acid sequence alignment of residues around the S1/S2 and S2′ cleavage sites of group 2b betacoronaviruses found in humans, civet cats, raccoon dog, pangolin, and bats (C) or coronaviruses that are able to infect humans (D). Basic amino acid residues are highlighted in red, while gray boxes mark the presence of multibasic motifs. Numbers refer to amino acid residues (n/a, no information available). The symbol "^∗^" refers to amino acid residues that are conserved among all tested sequences, while the symbols ":" and "." indicate positions with heterogeneous amino acid residues that share highly similar or similar biochemical properties.

Our previous work revealed that the activity of the cellular serine protease TMPRSS2, which activates several coronaviruses ([@bib2], [@bib5], [@bib7], [@bib20], [@bib29], [@bib30], [@bib31]), is also required for robust SARS-CoV-2 infection of human lung cells ([@bib10]). However, it is conceivable that the activity of other cellular proteases is also necessary. Thus, the Middle East respiratory syndrome coronavirus spike protein (MERS-S) is activated by a two-step process: MERS-S is first cleaved by furin at the S1/S2 site in infected cells, which is required for subsequent TMPRSS2-mediated cleavage at the S2′ site ([Figure 1](#fig1){ref-type="fig"}A) during viral entry into lung cells ([@bib13], [@bib24], [@bib22]). A cathepsin B/L-dependent auxiliary activation pathway is operative in many TMPRSS2^−^ cell lines but seems not to be available in viral target cells in the lung because TMPRSS2-dependent activation of the S protein is essential for robust MERS-CoV and SARS-CoV spread and pathogenesis in the infected host ([@bib12], [@bib32], [@bib41]).

The S1/S2 site in SARS-CoV-2 forms an exposed loop ([Figure 1](#fig1){ref-type="fig"}B) that harbors multiple arginine residues (multibasic) ([@bib33], [@bib37]) that are not found in SARS-CoV-related coronaviruses (SARSr-CoV) but are present in the human coronaviruses OC43, HKU1, and MERS-CoV ([Figure 1](#fig1){ref-type="fig"}C). However, the contribution of this multibasic cleavage site to SARS-CoV-2 infection of human cells is unknown and was in the focus of the present study.

Results {#sec2}
=======

The Multibasic S1/S2 Site in the Spike Protein of SARS-CoV-2 Is Required for Efficient Proteolytic Cleavage of the Spike Protein {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------

In order to address the role of the multibasic S1/S2 cleavage site in SARS-CoV-2 infection, we generated S protein mutants with altered S1/S2 cleavage sites ([Figure 2](#fig2){ref-type="fig"} A). In particular, we exchanged the multibasic cleavage site against its monobasic counterparts present in SARS-S or RaTG13-S ([Figure 2](#fig2){ref-type="fig"}A, RaTG13 is a bat coronavirus closely related to SARS-CoV-2 \[[@bib43]\]). This resulted in mutants SARS-2-S (SARS) and SARS-2-S (RaTG). Moreover, we either deleted all arginines in the S1/S2 site of SARS-2-S or inserted an additional arginine residue (jointly with an alanine to lysine exchange), giving rise to mutants SARS-2-S (delta) and SARS-2-S (opt), respectively. Finally, we introduced the S1/S2 sites of SARS-2-S and RaTG13-S into the background of SARS-S ([Figure 2](#fig2){ref-type="fig"}A), which yielded the mutants SARS-S (SARS-2) and SARS-S (RaTG).Figure 2The Multibasic S1/S2 Site of SARS-2-S Is Cleaved by Furin, and Cleavage Is Required for Syncytium Formation and Entry into Human Lung Cells(A) Overview of the SARS-S and SARS-2-S S1/S2 mutants analyzed.(B) Analysis of furin-mediated S protein priming. Rhabdoviral particles harboring the indicated S proteins containing a C-terminal V5 tag for detection were lysed and subjected to western blot analysis. Detection of vesicular stomatitis virus matrix protein (VSV-M) served as control.(C) Rhabdoviral particles bearing MERS-S, SARS-S, or SARS-2-S equipped with a V5 or HA epitope tag at their C terminus (or no glycoprotein at all, control) were produced in the absence or presence of furin inhibitor (FI, decanoyl-RVKR-CMK; 1 μM or 10 μM) and analyzed for S protein processing by western blot analysis. Detection of VSV-M served as control.(D) Syncytium formation assay: Vero or Vero-TMPRSS2 cells were transfected to express the indicated S proteins (or no S protein, empty vector, control). At 24 h post transfection, cells were incubated in the presence or absence of trypsin (1 μg/mL) for an additional 24 h before they were fixed, stained with May-Gruenwald and Giemsa solution, and analyzed by bright field microscopy (scale bars, 200 μm). White arrowheads indicate syncytia. For (B)--(D), representative data from three (B and C) or four (D) independent experiments are shown.(E) Transduction of Vero (TMPRSS2^−^) and Calu-3 (TMPRSS2^+^) cells with rhabdoviral particles bearing the indicated S proteins or vesicular stomatitis virus glycoprotein (VSV-G). At 16 h post transduction, virus-encoded firefly luciferase was quantified in cell lysates. Presented are the mean data from three independent experiments. Transduction efficiency is shown relative to that measured for particles not bearing a viral glycoprotein. Error bars indicate the standard error of the mean. Statistical significance was tested by one-way analysis of variance with Dunnett's post test (p \> 0.05, ns; ^∗∗∗^p ≤ 0.001).

The effects of the above described S1/S2 mutations on viral entry were examined using vesicular stomatitis virus (VSV) particles bearing S proteins because these particles are safe and adequately reflect coronavirus entry into target cells. Immunoblot of VSV particles bearing S proteins with a C-terminal antigenic tag revealed that all S proteins were readily incorporated into VSV particles. SARS-2-S WT (wild type) was efficiently cleaved at the S1/S2 site ([Figure 2](#fig2){ref-type="fig"}B), in keeping with published data ([@bib10], [@bib33]). Exchange of the S1/S2 site of SARS-2-S against those of SARS-S and RaTG13-S abrogated cleavage, and this effect was also seen when the multibasic motif was deleted ([Figure 2](#fig2){ref-type="fig"}B). Moreover, insertion of an additional arginine residue jointly with an alanine-to-lysine exchange at the S1/S2 site did not appreciably increase cleavability. Finally, insertion of the S1/S2 site of SARS-2-S into SARS-S increased S protein cleavability while insertion of the RaTG13 S1/S2 site did not ([Figure 2](#fig2){ref-type="fig"}B). These results indicate that the presence of several arginine residues at the S1/S2 site is required for efficient SARS-2-S proteolytic processing in human cells and also confers high cleavability to SARS-S.

Furin Cleaves the SARS-CoV-2 Spike Protein at the S1/S2 Site, and Cleavage Is Required for Efficient Cell-Cell Fusion {#sec2.2}
---------------------------------------------------------------------------------------------------------------------

We next investigated which protease is required for S protein processing at the S1/S2 site. The S1/S2 motif matches the minimal furin sequence RXXR and is closely related to the furin consensus sequence RX\[K/R\]R. Therefore, we analyzed whether decanoyl-RVKR-CMK, a furin inhibitor, blocks SARS-2-S processing at the S1/S2 site. Decanoyl-RVKR-CMK inhibited processing of MERS-S, which is known to depend on furin ([@bib6], [@bib22]), in a concentration-dependent manner and had no effect on SARS-S expression ([Figure 2](#fig2){ref-type="fig"}C), as expected. Processing of SARS-2-S was also inhibited, indicating that furin cleaves SARS-2-S at the S1/S2 site. In order to determine whether cleavage at the S1/S2 site is required for SARS-2-S-driven cell-cell fusion, we studied S-protein-dependent formation of multinucleated giant cells (syncytia). No syncytia were observed in the absence of S protein expression while MERS-S WT expression resulted in syncytium formation, which was increased upon addition of trypsin or expression of TMPRSS2 ([Figure 2](#fig2){ref-type="fig"}D). Expression of SARS-S WT or SARS-S harboring the S1/S2 site of RaTG13-S did not induce syncytium formation in the absence of protease, but modest multikaryon formation was detected in the presence of trypsin or TMPRSS2. In contrast, SARS-S harboring the SARS-2-S S1/S2 site induced syncytia in the absence of protease, and syncytium formation was markedly increased by trypsin and, particularly, TMPRSS2. SARS-2-S expression triggered syncytium formation that was strongly increased by trypsin and TMPRSS2. Syncytium formation was clearly less prominent and required the presence of trypsin or TMPRSS2 when the SARS-2-S S1/S2 site was replaced by that of SARS-S or RaTG13-S. Moreover, deletion of the multibasic motif resulted in a spike protein that was no longer able to induce syncytium formation even in the presence of trypsin or TMPRSS2. Finally, the addition of an arginine residue to the S1/S2 site of SARS-2-S jointly with alanine-to-lysine exchange strongly increased syncytium formation, indicating that viral variants with optimized S1/S2 sites might show augmented cell-cell spread and potentially altered pathogenicity. Thus, the S1/S2 site of SARS-2-S is required for cell-cell fusion, and this process can be augmented by adding basic residues to the S1/S2 site.

Cleavage of the SARS-CoV-2 Spike Protein at the S1/S2 Site Is Required for Viral Entry into Human Lung Cells {#sec2.3}
------------------------------------------------------------------------------------------------------------

We finally examined the importance of the S1/S2 site for S-protein-mediated virus-cell fusion. Blockade of SARS-2-S cleavage at the S1/S2 site (mutants SARS-2-S (SARS), SARS-2-S (RaTG), and SARS-2-S (delta)) abrogated entry into the TMPRSS2^+^ human lung cell line Calu-3 ([Figure 2](#fig2){ref-type="fig"}E), in which the cathepsin B/L-dependent S protein activation pathway is not sufficiently available ([@bib24]). In contrast, entry into TMPRSS2^−^ Vero cells, which is known to be cathepsin B/L dependent, was not affected by these mutations ([Figure 1](#fig1){ref-type="fig"}E), in keeping with results reported by Walls and colleagues ([@bib33]). Optimization of the S1/S2 site did not increase entry into the cell lines tested; it slightly decreased entry into both Vero and Calu-3 cells, for, at present, unclear reasons. Finally, alterations of the S1/S2 site of SARS-S did not augment entry efficiency. Collectively, these results demonstrate that a multibasic S1/S2 site is essential for SARS-2-S-driven entry into human lung cells while a monobasic site is sufficient for SARS-S.

Discussion {#sec3}
==========

Our results reveal commonalities between the proteolytic activation of SARS-CoV-2 and MERS-CoV. Both viruses depend on furin-mediated pre-cleavage of their S proteins at the S1/S2 site for subsequent S protein activation by TMPRSS2 in lung cells, which fail to express robust levels of cathepsin L ([@bib24]). Thus, inhibitors of furin and TMPRSS2 might be considered as a treatment option for COVID-19, and a TMPRSS2 inhibitor that blocks SARS-CoV-2 infection has recently been described ([@bib10]). Regarding furin inhibition, it must be taken into account that furin, unlike TMPRSS2, is required for normal development ([@bib25]). Blockade of this enzyme for prolonged time periods might thus be associated with unwanted toxic effects. In contrast, a brief treatment might be well tolerated and still associated with a therapeutic benefit ([@bib26], [@bib27]).

For avian influenza A viruses, a multibasic cleavage site in the viral hemagglutinin protein is a central virulence factor ([@bib18]). Thus, viruses with a monobasic cleavage site are activated by TMPRSS2 or related proteases with an expression profile confined to the aerodigestive tract. As a consequence, viral replication is limited to these organs and does not result in severe disease. In contrast, viruses with a multibasic cleavage site are activated by ubiquitously expressed proprotein convertases, including furin, and can thus spread systemically and cause massive disease. In the context of coronavirus infection, S protein cleavability has been identified as a determinant of zoonotic potential ([@bib21], [@bib38]). The presence of a highly cleavable S1/S2 site in SARS-2-S may therefore not have been unexpected. However, it is noteworthy that all SARS-CoV-2-related coronaviruses of bats and pangolins identified today harbor a monobasic cleavage site ([@bib16], [@bib17], [@bib40]). It will thus be interesting to determine how the multibasic motif was acquired by SARS-CoV-2, and a recent study suggested that a recombination event might have been responsible ([@bib40], [@bib42]).

Limitations of the Study {#sec3.1}
------------------------

Our results demonstrate that the multibasic S1/S2 cleavage site is essential for SARS-2-S-driven entry into TMPRSS2^+^ lung cells. It will be interesting to extend these studies to primary human respiratory epithelial cells and to authentic SARS-CoV-2, which requires a reverse genetics system not available to the present study.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Monoclonal anti-HA antibody produced in mouseSigma-AldrichCat.\#: H3663; RRID: [AB_262051](nif-antibody:AB_262051){#intref0010}Monoclonal anti-β-actin antibody produced in mouseSigma-AldrichCat.\#: A5441; RRID: [AB_476744](nif-antibody:AB_476744){#intref0015}Monoclonal anti-VSV-M (23H12) antibodyKeraFastCat.\#: EB0011; RRID: [AB_2734773](nif-antibody:AB_2734773){#intref0020}Monoclonal anti-mouse, peroxidase-coupledDianovaCat.\#: 115-035-003; RRID: [AB_10015289](nif-antibody:AB_10015289){#intref0025}Anti-VSV-G antibody (I1, produced from CRL-2700 mouse hybridoma cells)ATCCCat.\# CRL-2700; RRID: CVCL_G654**Bacterial and Virus Strains**VSV^∗^ΔG-FLuc[@bib1]N/AOne Shot™ OmniMAX™ 2 T1R Chemically Competent *E. coli*Thermo Fisher ScientificCat.\#: C854003**Chemicals, Peptides, and Recombinant Proteins**Lipofectamine LTX with Plus ReagentThermo Fisher ScientificCat.\#: 15338100Furin inhibitor, decanoyl-RVKR-CMKTocrisCat.\#: 3501May-Grünwald solutionSigma-AldrichCat.\#: 63590Giemsa solutionSigma-AldrichCat.\#: GS500**Critical Commercial Assays**Beetle-Juice KitPJKCat.\#: 102511**Experimental Models: Cell Lines**293TDSMZCat.\#: ACC-635; RRID: CVCL_0063Calu-3Laboratory of Stephan LudwigATCC Cat\# HTB-55; RRID: CVCL_0609VeroLaboratory of Andrea MaisnerATCC Cat\# CRL-1586; RRID: CVCL_0574Vero-TMPRSS2[@bib10]N/A**Oligonucleotides**SARS-S (BamHI) F CTTGGATCCGCCACCATGTTTATTTTC\
TTATTATTTCSigma-AldrichN/ASARS-SΔ18 (XbaI) R CTTTCTAGACTACTTGCAGCAAGAA\
CCACAAGAGCSigma-AldrichN/ASARS-SΔ18 (-)STOP (XbaI) R CTTTCTAGACTTGCAGCAAG\
AACCACAAGAGCSigma-AldrichN/ASARS-2-S (BamHI) F GAATTCGGATCCGCCACCATGTTCGT\
GTTTCTGGTGCTGCSigma-AldrichN/ASARS-2-SΔ18 (XbaI) R AAGGCCTCTAGACTACTTGCAGCA\
GCTGCCACAGCSigma-AldrichN/ASARS-2-SΔ18 (-)STOP (XbaI) R AAGGCCTCTAGACTTGCA\
GCAGCTGCCACAGCSigma-AldrichN/ASARS-S (SARS) F CAGACAAACAGCCCCAGACGGGCCAG\
AAGTACTAGCCAAAAATCTATTGSigma-AldrichN/ASARS-S (SARS) R TCTGGCCCGTCTGGGGCTGTTTGTCT\
GTGTATGGTAACTAGCACAAATGCSigma-AldrichN/ASARS-S (RaTG) F CAGACAAACAGCAGAAGTACTAGCCA\
AAAATCSigma-AldrichN/ASARS-S (RaTG) R TCTGCTGTTTGTCTGTGTATGGTAACTA\
GCACAAATGCSigma-AldrichN/ASARS-2-S (SARS) F GTTTCTTTATTACGTTCTGTGGCCAGC\
CAGAGCATCSigma-AldrichN/ASARS-2-S (SARS) R ACGTAATAAAGAAACTGTCTGGTAGC\
TGGCACAGATGSigma-AldrichN/ASARS-2-S (RaTG) F CAGACAAACAGCAGATCTGTGGCCAGC\
CAGAGCATCSigma-AldrichN/ASARS-2-S (RaTG) R GCTGGCCACAGATCTGCTGTTTGTCTG\
TGTCTGGTAGCSigma-AldrichN/ASARS-2-S (delta) F CAAACAGCCCCGCATCTGTGGCCAGCC\
AGAGCATCSigma-AldrichN/ASARS-2-S (delta) R GCTGGCCACAGATGCGGGGCTGTTTGTC\
TGTGTCTGGTAGCSigma-AldrichN/ASARS-2-S (opt) F CGAAGACGAAAAAGATCTGTGGCCAGCCA\
GAGCATCSigma-AldrichN/ASARS-2-S (opt) R TCTTTTTCGTCTTCGGCTGTTTGTCTGTGT\
CTGGSigma-AldrichN/ApCG1 Seq F CCTGGGCAACGTGCTGGTSigma-AldrichN/ApCG1 Seq R GTCAGATGCTCAAGGGGCTTCASigma-AldrichN/ASARS-S 387F TGTTATACGAGCATGTAACSigma-AldrichN/ASARS-S 790F AAGCCAACTACATTTATGCSigma-AldrichN/ASARS S 1194F TGATGTAAGACAAATAGCGSigma-AldrichN/ASARS S 1575F TATTAAGAACCAGTGTGTCSigma-AldrichN/ASARS S 1987F GTGCTAGTTACCATACAGSigma-AldrichN/ASARS S 2391F CTAAAGCCAACTAAGAGGSigma-AldrichN/ASARS S 2787F TCAACTGCATTGGGCAAGSigma-AldrichN/ASARS-2-S 651F CAAGATCTACAGCAAGCACACCSigma-AldrichN/ASARS-2-S 1380F GTCGGCGGCAACTACAATTACSigma-AldrichN/ASARS-2-S 1992F CTGTCTGATCGGAGCCGAGCACSigma-AldrichN/ASARS-2-S 2648F TGAGATGATCGCCCAGTACACSigma-AldrichN/ASARS-2-S 3286F GCCATCTGCCACGACGGCAAAGSigma-AldrichN/ApCG1-V5 F TCCCTAACCCTCTCCTCGGTCTCGATTCTACGTG\
AAAGCTGATCTTTTTCCCTCTGCCSigma-AldrichN/ApCG1-V5 R GACCGAGGAGAGGGTTAGGGATAGGCTTACCG\
CATGCCTGCAGGTTTAAACAGTCGSigma-AldrichN/ApCG1-XhoI R CTCCTCGAGTTCATAAGAGAAGAGGGSigma-AldrichN/A**Recombinant DNA**Plasmid: pCG1-SARS-S[@bib9]N/APlasmid: pCG1-SARS-S-HA[@bib10]N/APlasmid: pCG1-SARS-2-S[@bib10]N/APlasmid: pCG1-SARS-2-S-HA[@bib10]N/APlasmid: pCG1-SARS-SΔ18[@bib9]N/APlasmid: pCG1-SARS-SΔ18-V5This paperN/APlasmid: pCG1-SARS-2-SΔ18This paperN/APlasmid: pCG1-SARS-2-SΔ18-V5This paperN/APlasmid: pCG1-SARS-SΔ18 (SARS-2)This paperN/APlasmid: pCG1-SARS-SΔ18-V5 (SARS-2)This paperN/APlasmid: pCG1-SARS-SΔ18 (RaTG)This paperN/APlasmid: pCG1-SARS-SΔ18-V5 (RaTG)This paperN/APlasmid: pCG1-SARS-2-SΔ18 (SARS)This paperN/APlasmid: pCG1-SARS-2-SΔ18-V5 (SARS)This paperN/APlasmid: pCG1-SARS-2-SΔ18 (RaTG)This paperN/APlasmid: pCG1-SARS-2-SΔ18-V5 (RaTG)This paperN/APlasmid: pCG1-SARS-2-SΔ18 (delta)This paperN/APlasmid: pCG1-SARS-2-SΔ18-V5 (delta)This paperN/APlasmid: pCG1-SARS-2-SΔ18 (opt)This paperN/APlasmid: pCG1-SARS-2-SΔ18-V5 (opt)This paperN/APlasmid: pCAGGS-MERS-S-V5[@bib5]N/APlasmid: pCAGGS-VSV-G[@bib3]N/APlasmid: pCAGGS-DsRed[@bib9]N/APlasmid: pCG1Laboratory of Roberto CattaneoN/APlasmid: pCG1-V5This paperN/A**Software and Algorithms**Hidex Sense Microplate Reader SoftwareHidex Deutschland Vertrieb GmbH<https://www.hidex.de/>ChemoStar Imager Software (version v.0.3.23)Intas Science Imaging Instruments GmbH<https://www.intas.de/>ZEN imaging softwareCarl Zeiss<https://www.zeiss.com/>Clustal OmegaEuropean Molecular Biology Laboratory -- European Bioinformatics Institute (EMBL-EBI)<https://www.ebi.ac.uk/Tools/msa/clustalo/>; [@bib19]Adobe Photoshop CS5 Extended (version 12.0 3 32)Adobe<https://www.adobe.com/>GraphPad Prism (version 8.3.0(538))GraphPad Software<https://www.graphpad.com/>YASARA (version 19.1.27)YASARA Biosciences GmbH<http://www.yasara.org/>; [@bib15]Microsoft Office Standard 2010 (version 14.0.7232.5000)Microsoft Corporation<https://products.office.com/home>**Other**Prefusion structure of SARS-CoV spike glycoprotein (5X5B)[@bib39]<https://www.rcsb.org/structure/5X5B>

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stefan Pöhlmann (<spoehlmann@dpz.eu>).

### Materials Availability {#sec4.2.2}

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

### Data and Code Availability {#sec4.2.3}

The study did not generate unique datasets or code.

Method Details {#sec4.3}
--------------

### Cell cultures {#sec4.3.1}

293T (human, kidney) and Vero (African green monkey, kidney) cells were cultivated in Dulbecco's Modified Eagle Medium (PAN-Biotech) supplemented with 10% fetal bovine serum (Biochrom), 100 U/mL of penicillin and 0.1 mg/mL of streptomycin (PAN-Biotech). Vero cells that stably express human TMPRSS2 have been described previously ([@bib10]) and were cultivated in the presence of 10 μg/mL blasticidin (Invivogen). Calu-3 (human, lung; kindly provided by Stephan Ludwig, Westfälische Wilhelms-Universität, Muenster/Germany) cells were cultivated in Minimum Essential Medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Biochrom), 100 U/mL of penicillin and 0.1 mg/mL of streptomycin (PAN-Biotech), 1x non-essential amino acid solution (from 100x stock, PAA) and 10 mM sodium pyruvate (Thermo Fisher Scientific). All cell lines were incubated at 37°C and 5% CO~2~ in a humidified atmosphere.

### Plasmids {#sec4.3.2}

Expression plasmids for full-length vesicular stomatitis virus (VSV) glycoprotein (VSV-G), Middle-East respiratory syndrome coronavirus spike glycoprotein (MERS-S) containing a C-terminal V5 epitope tag, severe acute respiratory syndrome coronavirus spike glycoprotein (SARS-S) and severe acute respiratory syndrome coronavirus 2 spike glycoprotein (SARS-2-S) both equipped with a C-terminal hemagglutinin (HA) epitope tag have been described previously ([@bib3], [@bib10]). Empty pCG1 expression vector was kindly provided by Roberto Cattaneo, Mayo Clinic, Rochester, MN/USA). Based on the SARS-S and SARS-2-S expression plasmids we cloned mutated versions with alterations at the S1/S2 cleavage site: We generated SARS-S containing the cleavage site of SARS-2-S, SARS-S (SARS-2), or BetaCoV/bat/Yunnan/RaTG13/2013 (RaTG; GISAID: EPI_ISL_402131), SARS-S (RaTG). Further, we generated SARS-2-S harboring the S1/S2 cleavage site of SARS-S, SARS-2-S (SARS) or RaTG-S, SARS-2-S (RaTG). Finally, we constructed SARS-2-S variants in which either the multibasic motif was deleted, SARS-2-S (delta), or in which the proline residue preceding the multibasic motif was mutated to arginine and the alanine residue within the minimal furin motif was changed to lysine in order to increase the basic environment at the S1/S2 site, SARS-2-S (opt). All newly cloned spike protein constructs further contained a deletion of 18 amino acids at their respective C terminus as this has been shown to improve coronavirus spike protein incorporation into VSV particles and thus transduction ([@bib28]). Further, for each construct an untagged variant as well as a version containing a C-terminal V5 epitope tag was constructed.

### Preparation of pseudotyped particles and transduction experiments {#sec4.3.3}

A previously published protocol was employed to produce VSV pseudotype particles (VSVpp) carrying foreign viral glycoproteins in their envelope ([@bib1], [@bib14]). First, 293T cells were transfected with expression plasmid for the respective spike glycoprotein or VSV-G or empty expression vector by calcium-phosphate precipitation. At 16 h posttransfection, the cells were inoculated with VSV^∗^ΔG-fLuc (kindly provided by Gert Zimmer, Institute of Virology and Immunology, Mittelhäusern/Switzerland), a replication-deficient VSV vector that lacks the genetic information for VSV-G and encodes for eGFP and firefly luciferase (fLuc), at a multiplicity of infection of 3. After 1 h of incubation, the inoculum was removed and cells were washed with phosphate-buffered saline (PBS) before medium containing anti-VSV-G antibody (I1, mouse hybridoma supernatant from CRL-2700; ATCC) was added to all cells except for those expressing VSV-G (here, medium without antibody was added). Cells were further incubated for 16 h, before the VSVpp containing supernatants were harvested, freed from cellular debris by centrifugation and used for experiments.

For transduction, target cells were grown in 96-well plates until they reached 50%--80% confluency. The culture supernatant was removed by aspiration and 100 μl/well of the respective pseudotype were added (quadruplicate samples). At 16 h posttransduction, culture supernatants were aspirated and cells lysed in 1x cell culture lysis reagent (prepared from 5x stock, Promega) for 20 min at room temperature. The lysates were then transferred to white, opaque-walled 96-well plates and luciferase activity was quantified by measuring luminescence upon addition of a substrate (PJK) using a Hidex Sense plate luminometer (Hidex).

### Western blot analysis {#sec4.3.4}

For the analysis of S protein processing, we subjected VSVpp harboring V5- or HA-tagged S proteins to SDS-PAGE and western blot analysis. For this, we loaded 1 mL VSVpp onto 50 μl of a 20% (w/v) sucrose cushion and performed high-speed centrifugation (25.000 g for 120 min at 4°C). Next, we removed 1 mL of supernatant, added 50 μl of 2x SDS-sample buffer and incubated the samples for 15 min at 96°C. Thereafter, the samples were subjected to SDS-PAGE and protein transfer to nitrocellulose membranes by western blot. The membranes were subsequently blocked in 5% skim milk solution (PBS containing 0.05% Tween-20 \[PBS-T\] and 5% skim milk powder) for 1 h at room temperature. The blots were then incubated over night at 4°C with primary antibody solution (all antibodies were diluted in PBS-T containing 5% skim milk; mouse anti-HA tag \[Sigma-Aldrich, H3663, 1:2,500\], mouse anti-V5 tag \[Thermo Fisher Scientific, R960-25, 1:2,500\] or VSV matrix protein \[Kerafast, EB0011, 1:2,500\]). Following this incubation, the blots were washed 3x with PBS-T before they were incubated for 1 h at room temperature with peroxidase-coupled goat anti-mouse antibody (Dianova, 115-035-003, 1:10,000). Finally, the blots were again washed and imaged. For this, an in house-prepared enhanced chemiluminescent solution (0.1 M Tris-HCl \[pH 8.6\], 250 μg/mL luminol, 1 mg/mL para-hydroxycoumaric acid, 0.3% H~2~O~2~) and the ChemoCam imaging system along with the ChemoStar Professional software (Intas Science Imaging Instruments GmbH) were used.

### Syncytium formation assay {#sec4.3.5}

Vero or Vero-TMPRSS2 cells were grown on coverslips seeded in 24-well plates and transfected with S protein expression plasmids (1 μg/well) using Lipofectamine 2000 LTX with Plus reagent (Thermo Fisher Scientific) and OptiMEM medium (GIBCO). After 6 h the transfection solutions were aspirated and the cells further incubated for 24 h in standard culture medium. Next, the medium was changed to serum free medium ± 1 μg/mL bovine trypsin (Sigma-Aldrich) and the cells were incubated for additional 24 h. Then, the cells were washed with PBS, fixed with 4% paraformaldehyde solution for 20 min at room temperature, washed again, air-dried and incubated for 30 min with May-Gruenwald solution (Sigma-Aldrich). Thereafter, the cells were washed three times with deionized water, air-dried and incubated for 30 min with 1:10 diluted Giemsa solution (Sigma-Aldrich). After an additional washing interval with deionized water, the samples were air-dried and analyzed by bright-field microscopy using a Zeiss LSM800 confocal laser scanning microscope and the ZEN imaging software (both from Zeiss).

### Sequence analysis and protein models {#sec4.3.6}

Sequence alignments were performed using the Clustal Omega online tool (<https://www.ebi.ac.uk/Tools/msa/clustalo/>). Protein models were designed using the YASARA software (<http://www.yasara.org/index.html>). For the generation of the SARS-2-S protein model the protein sequence was first modeled on a SARS-S template (PDB: 5X5B, ([@bib39])) using the SWISS-MODEL online tool (<https://swissmodel.expasy.org/>). The following sequences information were obtained from National Center for Biotechnology Information (NCBI) database: SARS-CoV BJ01 (GenBank: AY278488.2), SARS-CoV CUHK-W1 (GenBank: AY278554.2), SARS-CoV Frankfurt-1 (GenBank: AY291315.1), SARS-CoV Tor2 (GenBank: CS050815.1), SARS-CoV Urbani (GenBank: AY278741.1), civet SARS-CoV SZ16 (GenBank: AY304488.1), civet SARS-CoV civet020 (GenBank: AY572038.1), raccoon dog SARS-CoV A030 (GenBank: AY687357.1), bat SARSr-CoV BtKY72/KEN (GenBank: KY352407.1), bat SARSr-CoV BM48-31/BGR/2008 (GenBank: GU190215.1), bat SARSr-CoV Rs4231 (GenBank: KY417146.1), bat SARSr-CoV WIV16 (GenBank: KT444582.1), bat SARSr-CoV Rs4874 (GenBank: KY417150.1), bat SARSr-CoV SL-CoVZC45 (GenBank: MG772933.1), bat SARSr-CoV SL-CoVZXC21 (GenBank: MG772934.1), bat SARSr-CoV LYRa11 (GenBank: KF569996.1), bat SARSr-CoV LYRa3 (GenBank: KF569997.1), bat SARSr-CoV WIV1 (GenBank: KF367457.1), bat SARSr-CoV RsSHC014 (GenBank: KC881005.1), bat SARSr-CoV Rs3367 (GenBank: KC881006.1), bat SARSr-CoV Cp/Yunnan2011 (GenBank: JX993988.1), bat SARSr-CoV Rp/Shaanxi2011 (GenBank: JX993987.1), bat SARSr-CoV HKU3-1 (GenBank: DQ022305.2), bat SARSr-CoV Rm1 (GenBank: DQ412043.1), bat SARSr-CoV Rp3 (GenBank: DQ071615.1), bat SARSr-CoV Rf1 (GenBank: DQ412042.1), bat SARSr-CoV 279 (GenBank: DQ648857.1), bat SARSr-CoV 273 (GenBank: DQ648856.1), bat SARSr-CoV YN2013 (GenBank: KJ473816.1), bat SARSr-CoV Rs/HuB2013 (GenBank: KJ473814.1), bat SARSr-CoV Rs/GX2013 (GenBank: KJ473815.1), bat SARSr-CoV Rf/SX2013 (GenBank: KJ473813.1), bat SARSr-CoV Rf/JL2012 (GenBank: KJ473811.1), bat SARSr-CoV Rf/HeB2013 (GenBank: KJ473812.1), bat SARSr-CoV YNLF/34C (GenBank: KP886809.1), bat SARSr-CoV YNLF/31C (GenBank: KP886808.1), bat SARSr-CoV Rs672 (GenBank: FJ588686.1), bat SARSr-CoV Rs7327 (GenBank: KY417151.1), bat SARSr-CoV Rs4084 (GenBank: KY417144.1), bat SARSr-CoV Rs9401 (GenBank: KY417152.1), bat SARSr-CoV Rs4247 (GenBank: KY417148.1), bat SARSr-CoV Rs4255 (GenBank: KY417149.1), bat SARSr-CoV Rs4081 (GenBank: KY417143.1), bat SARSr-CoV Rs4237 (GenBank: KY417147.1), bat SARSr-CoV As6526 (GenBank: KY417142.1), bat SARSr-CoV Rf4092 (GenBank: KY417145.1), bat SARSr-CoV Longquan-140 (GenBank: KF294457.1), bat SARSr-CoV Rs806 (GenBank: FJ588692.1), bat SARSr-CoV Anlong-103 (GenBank: KY770858.1), bat SARSr-CoV JTMC15 (GenBank: KU182964.1), bat SARSr-CoV 16BO133 (GenBank: KY938558.1), bat SARSr-CoV B15-21 (GenBank: KU528591.1), pangolin coronavirus MP789 (GenBank: MT084071.1). In addition the following sequences information were obtained from the Global Initiative on Sharing All Influenza Data (GISAID) database: SARS-CoV-2 (GISAID: EPI_ISL_404895), bat SARSr-CoV RaTG13 (GISAID: EPI_ISL_402131).

Quantification and Statistical Analysis {#sec4.4}
---------------------------------------

If not stated otherwise, statistical significance was tested by one-way analysis of variance with Dunnet's posttest (GraphPad Prism 7.03). Only p values of 0.05 or lower were considered statistically significant (p \> 0.05 \[ns, not significant\], p ≤ 0.05 \[^∗^\], p ≤ 0.01 \[^∗∗^\], p ≤ 0.001 \[^∗∗∗^\]). For all statistical analyses, the GraphPad Prism 7 software package was used (GraphPad Software).
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